Skip to content

Clinical Trial of Fetal Endotracheal Occlusion in fetuses with left sided isolated congenital diaphragmatic hernia

Clinical Trial of Fetal Endotracheal Occlusion in fetuses with left sided isolated congenital diaphragmatic hernia - Clinical trial of FETO

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012395
Enrollment
10
Registered
2013-11-25
Start date
2013-11-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal congenital diaphragmatic hernia

Interventions

A thin walled flexible Teflon cannula (3.3 mm
Performa, Cook, Strombeek Bever, Belgium), loaded with a pyramidal trocar (11650TG, Karl Storz, Germany) should be inserted into the amniotic cavity towards the fetal mouth. The trocar should then be
s solution heated to body temperature, for improving visualization and assist in dilatation of the vocal cords on entry of the trachea. The endoscope should be introduced into the fetal mouth, followi
Balt, Paris, France). Balloon retrieval should be planned at between 34+0 and 34+6 weeks. The options are ultrasound guided puncture and fetoscopic retrieval.

Sponsors

Japan Fetal Therapy Group (Fetus Japan)
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Between 27 and 31 weeks of gestation 2) Pregnant woman who is between 16 to 45 years old 3) Diagnosed as singleton with left sided isolated CDH 4) Diagnosed as left sided CDH with Liver up in the chest cavity and Stomach mainly in the right chest cavity (Grade 3 of Kitano classification) 5)O/E LHR < 45% 6) No other presence of fetal anomaies 7) No sign of pregnancy induced hypertension 8) No genital bleeding 9) No premature rupture of membrane 10) Greater than or equal to 20 mm of cervical length 11) Agreement of patient and her partner to follow the protocol

Exclusion criteria

Exclusion criteria: 1) Pregnant woman needs treatment for infectious disease. 2) Presence of HIV antibody, HCV antibody, or HBe antigen in pregnant women 3) Pregnant woman needs treatment for psychological problems 4) American Society of Anesthesiology (ASA) Physical Status Classification: Class 3, 4, 5, or 6

Design outcomes

Primary

MeasureTime frame
1) Complete FETO procedures without serious maternal side effects 2) survival till 90 postnatal days

Secondary

MeasureTime frame
1)Developmental milestones at 6 months after birth 2)Neurodevelopmental milestones at 6 months after birth 3)Adverse effects during FETO procedures 4)Unfixed balloon during and after FETO procedures 5)Lung size after FETO 6)Liver position after FETO 7)Stomach position after FETO 8)Preterm delivery after FETO 9)Intra-uterine fetal demise after FETO 10)Survival after FETO 11)Discharge without any serious complications 12)Number of days in neonatal intensive care unit after birth 13)Number of days of ventilatory support 14)Number of days of NO treatment 15)Complete surgery 16)Any other additional side effects

Countries

Japan

Contacts

Public ContactSeiji Wada MD PhD

National Center for Child Health and Development Department of Fetal Therapy

wada-s@ncchd.go.jp03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026